Sitagliptin Associated with Increase in Heart Failure Hospitalizations (FREE)
By Larry Husten Edited by Susan Sadoughi, MD, and Lorenzo Di Francesco, MD, FACP, FHM Use of the diabetes drug sitagliptin (Januvia) appears to be associated with increased risk for heart failure hospitalization among patients with preexisting heart failure, according to an … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - July 3, 2014 Category: Primary Care Source Type: news

Januvia Linked To Increase in Heart Failure Hospitalizations
The cardiovascular effects of drugs used for glucose control in patients with diabetes have been a subject of controversy for many years now. More recently, attention has started to focus specifically on the risk for heart failure. Now, an observational study will likely raise new questions about the dipeptidyl peptidase (DPP)-4 inhibitor sitagliptin (Januvia, Merck). (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - July 2, 2014 Category: Pharmaceuticals Authors: Larry Husten Source Type: news

Sitagliptin Linked to Higher HF Hospitalization Risk
(MedPage Today) -- In patients with type 2 diabetes and heart failure, the use of sitagliptin (Januvia) was associated with greater risk of hospitalization for heart failure, a study based on insurance claims showed. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - July 2, 2014 Category: Cardiology Source Type: news

Sitagliptin Linked to Higher HF Risk
(MedPage Today) -- In patients with type 2 diabetes and heart failure, the use of sitagliptin (Januvia) was associated with greater risk of hospitalization for heart failure, a study based on insurance claims showed. (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - July 2, 2014 Category: Primary Care Source Type: news

Conflicting Data on Sitagliptin and Heart Failure in Diabetes Conflicting Data on Sitagliptin and Heart Failure in Diabetes
One large real-world study finds no increased risk of heart failure among type 2 diabetes patients taking DPP-4 inhibitors, primarily sitagliptin. Another finds to the contrary. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 1, 2014 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Patients with type 2 diabetes taking JANUVIA® (sitagliptin), metformin initiated insulin therapy at a slower rate compared to patients taking a sulfonylurea, metformin
A late-breaking observational study has been released that assessed the differences in time to initiation of insulin use and the proportion of the population initiating insulin among patients with type 2 diabetes taking the combination of JANUVIA® (sitagliptin) and metformin, and patients taking the combination of a sulfonylurea and metformin. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - June 14, 2014 Category: Science Source Type: news

Patients with type 2 diabetes undergoing intensification of insulin therapy experienced less nighttime hypoglycemia while being treated with Januvia (Sitagliptin) compared to placebo
New post-hoc analysis shows patients with type 2 diabetes undergoing intensification of insulin therapy experienced less nighttime hypoglycemia while being treated with Januvia compared to placebo. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - June 14, 2014 Category: Science Source Type: news

Late-Breaking Observational Data Show Patients with Type 2 Diabetes Taking JANUVIA® (sitagliptin) and Metformin Initiated Insulin Therapy at a Slower Rate Compared to Patients Taking a Sulfonylurea and Metformin
In this study, patients treated with a combination of JANUVIA and metformin initiated insulin therapy at a slower rate during the period of observation than patients Language: English read more (Source: Merck.com - Research and Development News)
Source: Merck.com - Research and Development News - June 14, 2014 Category: Pharmaceuticals Tags: Research and Development News Source Type: news

New Post-Hoc Analysis Shows Patients with Type 2 Diabetes Undergoing Intensification of Insulin Therapy Experienced Less Nighttime Hypoglycemia While Being Treated with JANUVIA® (sitagliptin) Compared to Placebo
Dateline City: WHITEHOUSE STATION Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from a post-hoc analysis showing that patients with type 2 diabetes having treatment intensified with insulin glargine therapy while also being treated with JANUVIA® (sitagliptin) 100 mg once-daily had a lower incidence of nighttime (nocturnal) hypoglycemia compared to patients also receiving placebo. Results were presented at the American Diabetes Association 74th Scientific Sessions. Language: En...
Source: Merck.com - Research and Development News - June 14, 2014 Category: Pharmaceuticals Tags: Research and Development News Source Type: news

Late-breaking observational data show patients with type 2 diabetes taking JANUVIA® (sitagliptin) and metformin initiated insulin therapy at a slower rate compared to patients taking a sulfonylurea and metformin
(GCI Health NY) Merck, known as MSD outside the United States and Canada, today announced results from a late-breaking observational study that assessed the differences in time to initiation of insulin use and the proportion of the population initiating insulin among patients with type 2 diabetes taking the combination of JANUVIA® (sitagliptin) and metformin, and patients taking the combination of a sulfonylurea and metformin. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 14, 2014 Category: Global & Universal Source Type: news

New post-hoc analysis shows patients with type 2 diabetes undergoing intensification of insulin therapy experienced less nighttime hypoglycemia while being treated with Januvia (Sitagliptin) compared to placebo
(GCI Health NY) New post-hoc analysis shows patients with type 2 diabetes undergoing intensification of insulin therapy experienced less nighttime hypoglycemia while being treated with Januvia compared to placebo. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 14, 2014 Category: Global & Universal Source Type: news

Merck to Present New Clinical Data on JANUVIA® (Sitagliptin), Investigational Omarigliptin, and Real-World Data in Patients with Type 2 Diabetes at the 74th Scientific Sessions of the American Diabetes Association
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, will present 13 new studies and analyses, including data for its DPP-4 inhibitor JANUVIA® (sitagliptin) and for its investigational once-weekly DPP-4 inhibitor omarigliptin, at the 74th Scientific Sessions of the American Diabetes Association (ADA) being held in San Francisco, June 13-17, 2014. Several analyses of patient data in real-world settings will also be ...
Source: Merck.com - Corporate News - June 6, 2014 Category: Pharmaceuticals Tags: Corporate News Latest News Source Type: news

Featured in NEJM Journal Watch: Incretin-Based Diabetes Drugs Aren't Associated with Excess Risk for Acute Pancreatitis (FREE)
Extract Although not the final word, results of two large studies in BMJ should be reassuring for patients taking exenatide (Byetta) and sitagliptin (Januvia... (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - May 8, 2014 Category: Primary Care Source Type: news

AWARD-5: Dulaglutide Betters Sitagliptin in Type 2 DiabetesAWARD-5: Dulaglutide Betters Sitagliptin in Type 2 Diabetes
In patients with type 2 diabetes uncontrolled with metformin, adding weekly injections of dulaglutide led to better glycemic control at 1 year compared with adding oral sitagliptin, with acceptable safety. Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - April 28, 2014 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

A retrospective review of isolated gliptin-exposure cases reported to a state poison control system - Darracq MA, Toy JM, Chen T, Mo C, Cantrell FL.
Background. The dipeptidyl peptidase-4 (DPP-4) inhibitors sitagliptin, saxagliptin, and linagliptin are approved by the US Food and Drug Administration in the treatment of type-2 diabetes. Given the limited published information regarding human overdoses t... (Source: SafetyLit: All (Unduplicated))
Source: SafetyLit: All (Unduplicated) - March 15, 2014 Category: Global & Universal Tags: Poisoning Source Type: news